Bank of New York Mellon’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.28B | Buy |
6,753,962
+86,150
| +1% | +$16.2M | 0.21% | 81 |
|
|
2026
Q1 | $1.32B | Buy |
6,667,812
+6,151,812
| +1,192% | +$1.19B | 0.24% | 78 |
|
|
2025
Q4 | $94.9M | Buy |
516,000
+12,916
| +3% | +$2.27M | 0.02% | 673 |
|
|
2025
Q3 | $77.2M | Buy |
503,084
+40,285
| +9% | +$6.1M | 0.01% | 768 |
|
|
2025
Q2 | $64.7M | Sell |
462,799
-34,243
| -7% | -$4.8M | 0.01% | 833 |
|
|
2025
Q1 | $73.1M | Buy |
497,042
+34,778
| +8% | +$5.03M | 0.01% | 753 |
|
|
2024
Q4 | $60.6M | Sell |
462,264
-17,722
| -4% | -$2.48M | 0.01% | 883 |
|
|
2024
Q3 | $74.8M | Sell |
479,986
-33,352
| -6% | -$5.38M | 0.01% | 789 |
|
|
2024
Q2 | $80.1M | Sell |
513,338
-8,602
| -2% | -$1.29M | 0.02% | 761 |
|
|
2024
Q1 | $70.7M | Buy |
521,940
+11,169
| +2% | +$1.48M | 0.01% | 842 |
|
|
2023
Q4 | $68.8M | Buy |
510,771
+67,156
| +15% | +$8.73M | 0.01% | 845 |
|
|
2023
Q3 | $60.1M | Buy |
443,615
+22,752
| +5% | +$3.11M | 0.01% | 871 |
|
|
2023
Q2 | $60.2M | Sell |
420,863
-4,704
| -1% | -$692K | 0.01% | 901 |
|
|
2023
Q1 | $59.1M | Buy |
425,567
+813
| +0.2% | +$109K | 0.01% | 902 |
|
|
2022
Q4 | $57.6M | Buy |
424,754
+183
| +0% | +$22.9K | 0.01% | 898 |
|
|
2022
Q3 | $46.6M | Sell |
424,571
-10,986
| -3% | -$1.39M | 0.01% | 1007 |
|
|
2022
Q2 | $57.6M | Buy |
435,557
+10,907
| +3% | +$1.43M | 0.01% | 894 |
|
|
2022
Q1 | $56.3M | Buy |
424,650
+160,934
| +61% | +$19.3M | 0.01% | 1023 |
|
|
2021
Q4 | $30.7M | Sell |
263,716
-169,369
| -39% | -$19.9M | 0.01% | 1468 |
|
|
2021
Q3 | $52M | Buy |
433,085
+336,571
| +349% | +$39.2M | 0.01% | 1095 |
|
|
2021
Q2 | $11.6M | Buy |
96,514
+1,636
| +2% | +$179K | ﹤0.01% | 2049 |
|
|
2021
Q1 | $9.44M | Buy |
94,878
+5,868
| +7% | +$590K | ﹤0.01% | 2117 |
|
|
2020
Q4 | $8.9M | Sell |
89,010
-11,954
| -12% | -$1.27M | ﹤0.01% | 2065 |
|
|
2020
Q3 | $11.1M | Sell |
100,964
-4,842
| -5% | -$539K | ﹤0.01% | 1800 |
|
|
2020
Q2 | $11.2M | Buy |
105,806
+49,487
| +88% | +$5.11M | ﹤0.01% | 1768 |
|
|
2020
Q1 | $5.03M | Sell |
56,319
-400
| -0.7% | -$37.7K | ﹤0.01% | 2072 |
|
|
2019
Q4 | $5.66M | Buy |
56,719
+1,738
| +3% | +$164K | ﹤0.01% | 2274 |
|
|
2019
Q3 | $4.9M | Sell |
54,981
-2,489
| -4% | -$216K | ﹤0.01% | 2299 |
|
|
2019
Q2 | $4.75M | Sell |
57,470
-18,019
| -24% | -$1.41M | ﹤0.01% | 2356 |
|
|
2019
Q1 | $6.1M | Sell |
75,489
-12,333
| -14% | -$972K | ﹤0.01% | 2239 |
|
|
2018
Q4 | $6.67M | Sell |
87,822
-6,346
| -7% | -$496K | ﹤0.01% | 2127 |
|
|
2018
Q3 | $7.45M | Buy |
94,168
+5,280
| +6% | +$399K | ﹤0.01% | 2195 |
|
|
2018
Q2 | $6.24M | Sell |
88,888
-4,713
| -5% | -$339K | ﹤0.01% | 2275 |
|
|
2018
Q1 | $6.55M | Sell |
93,601
-16,841
| -15% | -$1.17M | ﹤0.01% | 2205 |
|
|
2017
Q4 | $7.67M | Buy |
110,442
+1,270
| +1% | +$85.6K | ﹤0.01% | 2121 |
|
|
2017
Q3 | $7.4M | Buy |
109,172
+11,189
| +11% | +$707K | ﹤0.01% | 2151 |
|
|
2017
Q2 | $6.68M | Buy |
97,983
+5,656
| +6% | +$369K | ﹤0.01% | 2180 |
|
|
2017
Q1 | $5.75M | Buy |
92,327
+11,679
| +14% | +$680K | ﹤0.01% | 2262 |
|
|
2016
Q4 | $4.41M | Sell |
80,648
-13,627
| -14% | -$774K | ﹤0.01% | 2383 |
|
|
2016
Q3 | $6.2M | Buy |
94,275
+31,058
| +49% | +$2.03M | ﹤0.01% | 2131 |
|
|
2016
Q2 | $3.82M | Buy |
63,217
+6,609
| +12% | +$384K | ﹤0.01% | 2348 |
|
|
2016
Q1 | $3.19M | Sell |
56,608
-19,802
| -26% | -$1.19M | ﹤0.01% | 2409 |
|
|
2015
Q4 | $5.19M | Sell |
76,410
-3,187
| -4% | -$209K | ﹤0.01% | 2191 |
|
|
2015
Q3 | $5.07M | Sell |
79,597
-7,208
| -8% | -$474K | ﹤0.01% | 2223 |
|
|
2015
Q2 | $5.53M | Sell |
86,805
-44,465
| -34% | -$3.04M | ﹤0.01% | 2288 |
|
|
2015
Q1 | $8.98M | Sell |
131,270
-15,395
| -10% | -$1.07M | ﹤0.01% | 2003 |
|
|
2014
Q4 | $10.3M | Sell |
146,665
-1,027
| -0.7% | -$73.5K | ﹤0.01% | 1893 |
|
|
2014
Q3 | $10.6M | Sell |
147,692
-89,183
| -38% | -$6.53M | ﹤0.01% | 1863 |
|
|
2014
Q2 | $17.6M | Buy |
236,875
+55,580
| +31% | +$4.02M | ﹤0.01% | 1560 |
|
|
2014
Q1 | $11.8M | Sell |
181,295
-46,206
| -20% | -$2.98M | ﹤0.01% | 1803 |
|
|
2013
Q4 | $13.5M | Sell |
227,501
-8,479
| -4% | -$461K | ﹤0.01% | 1703 |
|
|
2013
Q3 | $12.3M | Buy |
235,980
+15,635
| +7% | +$785K | ﹤0.01% | 1722 |
|
|
2013
Q2 | $10.4M | Buy |
+220,345
| New | +$11.2M | ﹤0.01% | 1759 |
|
Other funds holding AZN
EP
IA
Bank of New York Mellon's AZN Position: Q2 2026 in Review
Bank of New York Mellon increased its AstraZeneca (AZN) stake by 1.3% in Q2 2026, buying an estimated $16.2M and bringing the position to 6,753,962 shares worth $1.28B. The position accounts for 0.21% of the portfolio, ranked #81.
Bank of New York Mellon first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.32B in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Bank of New York Mellon held 6,753,962 shares of AstraZeneca worth $1.28B as of Q2 2026.
- Bank of New York Mellon bought 86,150 AstraZeneca shares in Q2 2026, an estimated $16.2M.
- AstraZeneca made up 0.21% of Bank of New York Mellon's portfolio in Q2 2026, its #81 holding.
- Bank of New York Mellon first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's AstraZeneca position peaked at $1.32B in Q1 2026.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.